Macrophages in prostate cancer: dual roles in tumor progression and immune evasion

前列腺癌中的巨噬细胞:在肿瘤进展和免疫逃逸中的双重作用

阅读:1

Abstract

Prostate malignant tumors are notably common within the male urinary tract and present significant challenges in medical treatment. A crucial aspect of understanding the progression of these tumors involves examining the immune microenvironment, particularly the multifaceted role played by macrophages. These immune cells have dual functions: on the one hand, they can inhibit tumor growth, while on the other hand, they can also facilitate and accelerate the progression of prostate cancer. Investigations have shed light on the mechanisms through which macrophages contribute to cancer promotion. These mechanisms include their involvement in mediating inflammatory responses, the secretion of chemokines that attract other immune cells, and the production of macrophage extracellular traps (METs), all of which may create favorable environments for tumor development. In the context of advanced prostate cancer, immunotherapy has emerged as the primary treatment modality. However, the effectiveness of this approach often falls short, leading to disheartening prognoses for patients undergoing such therapies. The suboptimal efficacy and poor outcomes associated with immunotherapy may be correlated with the activity of macrophages within the tumor microenvironment (TME). Specifically, the infiltration of macrophages into tumor tissues, along with elevated levels of these cells in the peripheral blood, has been identified as an indicator of a poor prognosis for individuals with prostate cancer. This study provides a deeper understanding of the cancer-promoting effects of macrophages and the various mechanisms by which they operate, including the roles of chemokines and the production of macrophage extracellular traps in both the onset and progression of prostate cancer. Furthermore, we explored how these factors are related to local tumor infiltration and systemic macrophage counts, which are associated with unfavorable survival outcomes for patients with this disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。